UNSPSC 51171848: Pipamazine

This classification denotes an antiemetic agent with the molecular formula C21H24ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 653552FH1N, chemically known as isonipecotamide, 1-(3-(2-chlorophenothiazin-10-yl)propyl)- but generally known as pipamazine, which bears US NIH Compound Identifier 6761. European Medicines Agency schedules Pipamazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09859MIG.

UNSPSC 51171848 Pipamazine (Commodity) covers drug-testing reagents and screening compounds used in offender supervision, workplace drug screening, and pharmacy benefit management programs across state and local jurisdictions. Recent opportunities show state and local agencies soliciting pipamazine and related screening agents as components of broader drug-testing services, pharmaceutical supply contracts, and pharmacy benefit initiatives rather than as standalone chemical purchases.

State and local issuing bodies pursuing pipamazine-related services include county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services due July 23, 2026, requesting immunoassay screening with LC/MS/MS or GC/MS confirmation across approximately 25,031 annual tests at an estimated contract value of $600,000 over two years with optional three-year renewals; this procurement spans staffing, lab operations, and reagent supply for five-panel and six-panel drug screens. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for direct-to-manufacturer pharmaceutical programs, signaling state interest in optimizing drug-testing and pharmacy supply chains outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026; vendors must maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act requirements. Recent activity concentrates in Texas and the Upper Midwest, with opportunities emphasizing regulatory certification (SAMHSA, Texas DPS, CAP lab accreditation), wholesaler-authorized distribution channels, and fixed or negotiated net pricing models in multi-year term contracts.